Aurobindo Files First Biosimilar In Europe With Pegfilgrastim
Indian Giant’s CuraTeQ Subsidiary Files BP14 Neulasta Rival With EMA
Executive Summary
Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.
You may also be interested in...
Aurobindo Seeks To Boost India Business With Veritaz Acquisition
Aurobindo is looking to grow its business in India by acquiring Veritaz’s domestic formulations operations in a $22.4m slump sale.
Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit
Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock.
Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit
Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock